Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal albumin-bound paclitaxel plus intravenous sintilimab-SOX for newly diagnosed gastric cancer with peritoneal metastasis
ChiCTR2300068976Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, sintilimab, oxaliplatin and tegafur in gastric cancer (GC) and peritoneal carcinomatosis (PC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Progression-free survival and Translational success rate. Started Mar 2023; status: recruiting.
02
Drugs
paclitaxelsintilimaboxaliplatintegafur
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR2300068976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068976.